MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
复制标题
DOI：
10.1186/1476-4598-13-129
复制
发表时间：
2014-05-29
期刊：
影响因子：
37.3
通讯作者：
Patankar MS
中科院分区：
文献类型：
--
作者：
Felder M;Kapur A;Gonzalez-Bosquet J;Horibata S;Heintz J;Albrecht R;Fass L;Kaur J;Hu K;Shojaei H;Whelan RJ;Patankar MS
自首次报道CA 125在卵巢肿瘤中的表达以来，已经过去了三十多年。从那时起，我们对卵巢癌生物学的理解发生了重大变化，现在这些肿瘤的分类是基于分子表型，而不是纯粹的组织学属性。然而，CA 125仍然是卵巢癌的唯一临床可靠的诊断标志物，最近的例外是HE 4。许多大规模的临床试验已经进行或正在进行中，以确定血清CA 125水平作为筛查方式或区分良性和恶性盆腔肿块的潜在用途。CA 125是3-5百万Da粘蛋白MUC 16的肽表位。在这里，我们提供了一个深入的文献回顾，突出CA 125作为卵巢癌的预后和诊断标志物的重要性。我们关注越来越多的文献描述MUC 16在卵巢肿瘤进展和转移中的生物学作用。最后，我们考虑了以前和正在进行的努力，以开发治疗方法，以消除卵巢肿瘤的目标MUC 16。尽管CA 125是卵巢癌的重要标志物，但该抗原的确切结构定义仍然难以捉摸。MUC 16/CA 125在卵巢癌的诊断、进展和治疗中的重要性使得需要对这种粘蛋白的生物化学和生物学进行深入研究。对MUC 16的重新关注可能会导致卵巢癌检测和治疗的新的和更有效的策略。
Over three decades have passed since the first report on the expression of CA125 by ovarian tumors. Since that time our understanding of ovarian cancer biology has changed significantly to the point that these tumors are now classified based on molecular phenotype and not purely on histological attributes. However, CA125 continues to be, with the recent exception of HE4, the only clinically reliable diagnostic marker for ovarian cancer. Many large-scale clinical trials have been conducted or are underway to determine potential use of serum CA125 levels as a screening modality or to distinguish between benign and malignant pelvic masses. CA125 is a peptide epitope of a 3–5 million Da mucin, MUC16. Here we provide an in-depth review of the literature to highlight the importance of CA125 as a prognostic and diagnostic marker for ovarian cancer. We focus on the increasing body of literature describing the biological role of MUC16 in the progression and metastasis of ovarian tumors. Finally, we consider previous and on-going efforts to develop therapeutic approaches to eradicate ovarian tumors by targeting MUC16. Even though CA125 is a crucial marker for ovarian cancer, the exact structural definition of this antigen continues to be elusive. The importance of MUC16/CA125 in the diagnosis, progression and therapy of ovarian cancer warrants the need for in-depth research on the biochemistry and biology of this mucin. A renewed focus on MUC16 is likely to culminate in novel and more efficient strategies for the detection and treatment of ovarian cancer.
登录
查看更多内容
影响因子：
6.4
作者：
Belisle, Jennifer A.;Gubbels, Jennifer A. A.;Patankar, Manish S.
通讯作者：
Patankar, Manish S.
影响因子：
2
作者：
Bast, RC;Xu, FJ;Mills, GB
通讯作者：
Mills, GB
影响因子：
--
作者：
Berman, Zach T.;Moore, Lee J.;Whelan, Rebecca J.
通讯作者：
Whelan, Rebecca J.
DOI：
10.1097/igc.0b013e318251c97d
发表时间：
2012-05
期刊：
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
影响因子：
--
作者：
Bast RC Jr;Skates S;Lokshin A;Moore RG
通讯作者：
Moore RG
影响因子：
4.6
作者：
Berek, JS
通讯作者：
Berek, JS